11 research outputs found
Influence of superionic nanoparticles CuβPSβ I on dielectric properties of nematic liquid crystal 6Π‘ΠΠΠ’
Within the frequency range 10β¦10βΆ Hz, the influence of CuβPSβ
I nanoparticles on the dielectric properties of planar oriented liquid crystal 6Π‘ΠΠΠ’ has been studied. It has been shown that nanoparticles lead to an increase in conductivity, but the conductivity dependence on concentration is non-monotonic function. It has been suggested that the reason of non-monotonic dependence of conductivity of 6Π‘ΠΠΠ’ on the concentration of nanoparticles is significant influence of ion adsorption on the nanoparticle surface and increase in the viscosity of liquid crystal when introducing nanoparticles
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· Π»Π΅ΡΠ΅Π½ΠΈΡ Π²Π·ΡΠΎΡΠ»ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ: ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π± ΠΈ ΠΎΠΌΠ°Π»ΠΈΠ·ΡΠΌΠ°Π±
Objective: Based on the cost-effectiveness analysis (CEA) to determine economic and clinical consequences of using mepolizumab instead of omalizumab in adults with severe eosinophilic asthma, when omalizumab is administered once every 2 weeks or mepolizumab is administered once every 4 weeks. Methods: Effectiveness and safety analysis was conducted based on the published network meta-analysis, because head-to-head clinical trials of omalizumab versus mepolizumab were not identified during targeted scientific literature search. Direct medical costs were calculated using information from the register of manufacturers' maximum selling prices for vital and essential drugs (VED), instructions for medical use, the unit cost of healthcare services. Results: Effectiveness and safety of the compared drugs were determined based on the results of the network meta-analysis. Frequency of clinically significant asthma exacerbations (risk ratio = 0,19; 95% CI: 0,02-2,32) and withdrawals due to adverse events (risk ratio = 0,05; 95% CI: 0,002-0,95). Therefore, despite the tendency to mepolisumab benefits, it was concluded that there are no statistically significant differences in the effectiveness and safety of the compared drugs due to the insufficient statistical power of the result. Direct medical costs were 870130 rubles and 1852063 rubles for mepolizumab and omalizumab respectively. Saving of direct medical costs for mepolizumab treatment was 959170 rubles per patient per year or 52%. Conclusion: treatment with mepolizumab versus omalizumab in patients with severe eosinophilic asthma, when omalizumab is administered once every 2 weeks or mepolizumab is administered once every 4 weeks, leads to saving of direct medical costs for drug treatment.Π¦Π΅Π»Ρ: ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ΅Π»Π΅Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ (ΠΠΠ) Π²ΡΡΠ²ΠΈΡΡ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΠ²ΠΈΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° Π²ΠΌΠ΅ΡΡΠΎ ΠΎΠΌΠ°Π»ΠΈΠ·ΡΠΌΠ°Π±Π° Ρ Π²Π·ΡΠΎΡΠ»ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ (ΠΠ), ΠΊΠΎΡΠΎΡΡΠΌ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ Π½Π°Π·Π½Π°ΡΠ΅Π½ ΠΎΠΌΠ°Π»ΠΈΠ·ΡΠΌΠ°Π± Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ 1 ΡΠ°Π· Π² Π΄Π²Π΅ Π½Π΅Π΄Π΅Π»ΠΈ ΠΈΠ»ΠΈ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π± Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ 1 ΡΠ°Π· Π² 4 Π½Π΅Π΄Π΅Π»ΠΈ. ΠΠ΅ΡΠΎΠ΄ΠΈΠΊΠ°: ΠΠ½Π°Π»ΠΈΠ· ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π±ΡΠ» ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π²ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°-Π°Π½Π°Π»ΠΈΠ·Π°, ΡΠ°ΠΊ ΠΊΠ°ΠΊ ΠΏΡΡΠΌΡΠ΅ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΠΌΠ°Π»ΠΈΠ·ΡΠΌΠ°Π±Π° ΠΈ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° Π½Π΅ Π±ΡΠ»ΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ Π² Ρ
ΠΎΠ΄Π΅ ΡΠ΅Π»Π΅Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΠΎΠ³ΠΎ Π½Π°ΡΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠΈΡΠΊΠ°. Π‘ΡΠΌΠΌΠ° ΠΏΡΡΠΌΡΡ
ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
Π·Π°ΡΡΠ°Ρ Π±ΡΠ»Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π° Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΈΠ· ΡΠ΅Π΅ΡΡΡΠ° ΠΏΡΠ΅Π΄Π΅Π»ΡΠ½ΡΡ
ΠΎΡΠΏΡΡΠΊΠ½ΡΡ
ΡΠ΅Π½ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ ΠΆΠΈΠ·Π½Π΅Π½Π½ΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡΡ
ΠΈ Π²Π°ΠΆΠ½Π΅ΠΉΡΠΈΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² (ΠΠΠΠΠ), ΠΈΠ½ΡΡΡΡΠΊΡΠΈΠΉ ΠΏΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΌΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ, Π½ΠΎΡΠΌΠ°ΡΠΈΠ²ΠΎΠ² ΡΠΈΠ½Π°Π½ΡΠΎΠ²ΡΡ
Π·Π°ΡΡΠ°Ρ Π½Π° Π΅Π΄ΠΈΠ½ΠΈΡΡ ΠΎΠ±ΡΠ΅ΠΌΠ° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΡΠ΅ΡΠ΅Π²ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°-Π°Π½Π°Π»ΠΈΠ·Π° Π±ΡΠ»Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΡΡΠ°Π²Π½ΠΈΠ²Π°Π΅ΠΌΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². Π§Π°ΡΡΠΎΡΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ ΠΠ (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠΎΠ² = 0,19; 95% Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π»-ΠΠ: 0,02-2.32) ΠΈ ΠΏΡΠ΅ΠΊΡΠ°ΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ·-Π·Π° Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ²Π»Π΅Π½ΠΈΠΉ (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠΎΠ² = 0,05; 95% ΠΠ: 0,002-0,95). Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π½Π΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π°ΠΌ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±Π°, Π±ΡΠ»ΠΎ ΡΠ΄Π΅Π»Π°Π½ΠΎ Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΠΎΠ± ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΌΠ΅ΠΆΠ΄Ρ 74 ΡΡΠ°Π²Π½ΠΈΠ²Π°Π΅ΠΌΡΠΌΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ ΠΏΠΎ ΠΏΡΠΈΡΠΈΠ½Π΅ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠΎΡΠ½ΠΎΡΡΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
Π΄Π°Π½Π½ΡΡ
. Π‘ΡΠΌΠΌΠ° ΠΏΡΡΠΌΡΡ
ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
Π·Π°ΡΡΠ°Ρ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 870 130 ΡΡΠ±. ΠΈ 1 852 063 ΡΡΠ±. Π΄Π»Ρ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° ΠΈ ΠΎΠΌΠ°Π»ΠΈΠ·ΡΠΌΠ°Π±Π° ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠΊΠΎΠ½ΠΎΠΌΠΈΡ ΠΏΡΡΠΌΡΡ
ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
Π·Π°ΡΡΠ°Ρ ΠΏΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 959 170 ΡΡΠ±. Π½Π° ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π² Π³ΠΎΠ΄ ΠΈΠ»ΠΈ 52%. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅: ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° Π²ΠΌΠ΅ΡΡΠΎ ΠΎΠΌΠ°Π»ΠΈΠ·ΡΠΌΠ°Π±Π° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΠ, ΠΊΠΎΡΠΎΡΡΠΌ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ Π½Π°Π·Π½Π°ΡΠ΅Π½ ΠΎΠΌΠ°Π»ΠΈΠ·ΡΠΌΠ°Π± Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ 1 ΡΠ°Π· Π² 2 Π½Π΅Π΄Π΅Π»ΠΈ ΠΈΠ»ΠΈ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π± 1 ΡΠ°Π· Π² 4 Π½Π΅Π΄Π΅Π»ΠΈ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΠΈ ΠΏΡΡΠΌΡΡ
ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
Π·Π°ΡΡΠ°Ρ Π½Π° Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ
ΠΠ°ΠΊΡΠΈΠ½ΠΎΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Ρ Π²Π·ΡΠΎΡΠ»ΡΡ . Π Π΅Π·ΠΎΠ»ΡΡΠΈΡ ΡΠΎΠ²Π΅ΡΠ° ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ² (ΠΠΎΡΠΊΠ²Π°, 16 Π΄Π΅ΠΊΠ°Π±ΡΡ 2017 Π³.)
The following key issues of pneumococcal infection prophylaxis were discussed during the expert council: incidence rates of community-acquired pneumococcal pneumonia and other pneumococcal infections, local epidemiological data, increases in antimicrobial resistance and pneumococcal serotypes substitution, current international and Russian clinical guidelines, practical approaches, and pneumococcal vaccination coverage of adult population in the Russian Federation. The agreement between the experts about a need to distinguish the use of conjugate vaccines and polysaccharide vaccines in different subpopulations has been achieved.Π Ρ
ΠΎΠ΄Π΅ ΡΠΎΠ²Π΅ΡΠ° ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ² ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½Ρ ΠΊΠ»ΡΡΠ΅Π²ΡΠ΅ Π²ΠΎΠΏΡΠΎΡΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ (ΠΠ): ΡΠΈΡΡΠ°ΡΠΈΡ Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡΡ Π²Π½Π΅Π±ΠΎΠ»ΡΠ½ΠΈΡΠ½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠ΅ΠΉ (ΠΠ) ΠΈ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΠ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π»ΠΎΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΡΠΎΡΡΠ° ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΈ Π·Π°ΠΌΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΠ°ΠΌΠΌΠΎΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠ°, ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΠ΅ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠ΅ ΠΈ ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ, ΡΠ΅ΠΊΡΡΠΈΠ΅ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ, ΠΎΡ
Π²Π°Ρ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠ΅ΠΉ Π²Π·ΡΠΎΡΠ»ΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π Π€. Π‘ΡΠΎΡΠΌΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΎ ΠΊΠΎΠ½ΡΠΎΠ»ΠΈΠ΄ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΌΠ½Π΅Π½ΠΈΠ΅ ΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΡΠ°Π·Π³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΈ ΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄Π½ΡΡ
Π²Π°ΠΊΡΠΈΠ½ Π² ΡΠ°Π·Π½ΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ
Severe bronchial asthma patient care organization in various regions of the Russian Federation. From endotypes and phenotypes of bronchial asthma to personalized choice of therapy
Β© 2020 Consilium Medikum. All rights reserved. The meeting of the Expert board was held in Moscow on June 24, 2019, at which the following issues were considered: the applicability of a new terminology characterizing asthma endotypes and phenotypes in real clinical practice, the effect of phenotypes and biomarkers in patients with bronchial asthma on the choice of biological drug, as well as the optimal clinical profiles of patients for whom dupilumab is most effective, taking into account the data of the III phase clinical trials, regional features of medical care and changes in updated international clinical guidelines for the diagnosis and treatment of asthma. The Expert board included members of leading Russian scientific and educational medical institutions: S.N. Avdeev, corresponding member of the Russian Academy of Sciences, prof., MD; O.A. Volkova, Ph.D.; I.V. Demko, prof., MD; G.L. Ignatova, prof., MD; I.V. Leshchenko, prof., MD; Kanukova N.A.; Kudelya L.M., prof., MD; V.A. Nevzorova, prof., MD; N.G. Nedashkovskaya; O.P. Ukhanova, prof., MD; L.V. Shulzhenko, prof., MD; R.S. Fassakhov, prof., MD
ΠΠ°ΠΊΡΠΈΠ½ΠΎΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Ρ Π²Π·ΡΠΎΡΠ»ΡΡ . Π Π΅Π·ΠΎΠ»ΡΡΠΈΡ ΡΠΎΠ²Π΅ΡΠ° ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ² (ΠΠΎΡΠΊΠ²Π°, 16 Π΄Π΅ΠΊΠ°Π±ΡΡ 2017 Π³.)
The following key issues of pneumococcal infection prophylaxis were discussed during the expert council: incidence rates of community-acquired pneumococcal pneumonia and other pneumococcal infections, local epidemiological data, increases in antimicrobial resistance and pneumococcal serotypes substitution, current international and Russian clinical guidelines, practical approaches, and pneumococcal vaccination coverage of adult population in the Russian Federation. The agreement between the experts about a need to distinguish the use of conjugate vaccines and polysaccharide vaccines in different subpopulations has been achieved.Π Ρ
ΠΎΠ΄Π΅ ΡΠΎΠ²Π΅ΡΠ° ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ² ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½Ρ ΠΊΠ»ΡΡΠ΅Π²ΡΠ΅ Π²ΠΎΠΏΡΠΎΡΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ (ΠΠ): ΡΠΈΡΡΠ°ΡΠΈΡ Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡΡ Π²Π½Π΅Π±ΠΎΠ»ΡΠ½ΠΈΡΠ½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠ΅ΠΉ (ΠΠ) ΠΈ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΠ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π»ΠΎΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΡΠΎΡΡΠ° ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΈ Π·Π°ΠΌΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΠ°ΠΌΠΌΠΎΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠ°, ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΠ΅ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠ΅ ΠΈ ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ, ΡΠ΅ΠΊΡΡΠΈΠ΅ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ, ΠΎΡ
Π²Π°Ρ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠ΅ΠΉ Π²Π·ΡΠΎΡΠ»ΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π Π€. Π‘ΡΠΎΡΠΌΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΎ ΠΊΠΎΠ½ΡΠΎΠ»ΠΈΠ΄ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΌΠ½Π΅Π½ΠΈΠ΅ ΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΡΠ°Π·Π³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΈ ΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄Π½ΡΡ
Π²Π°ΠΊΡΠΈΠ½ Π² ΡΠ°Π·Π½ΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ
Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype
Β© 2020 Medical Education. All rights reserved. Biological therapy of bronchial asthma (BA) is a modern method of treating severe forms of the disease, that are uncontrolled by traditional pharmacotherapeutic approaches. Currently, 5 monoclonal antibody (AT) preparations are registered in the world for the treatment of severe bronchial asthma (SBA) of the T2 endotype (T2-SBA) - antibodies, binding to immunoglobulin (Ig) E (anti-IgE - omalizumab), interleukin antagonists (IL)-5 (anti-IL-5 - mepolizumab, resizumab) and its receptor (anti-IL-5RΞ± - benralizumab), as well as antibodies, that selectively bind to the IL-4 and -13 receptor (anti-IL-4 /13RΞ± - dupilumab). The article presents data on the effectiveness of these drugs in relation to the key characteristics of SBA, formulates clinical and laboratory criteria, the study of which in real practice can potentially predict the likelihood of a clinical response to a particular type of biological therapy. An algorithm is proposed for choosing a targeted therapy strategy for patients with SBA, clinically associated with allergies, for patients with severe non-allergic eosinophilic BA and for patients with eosinophilic BA of a combined phenotype